Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 22 Mar 2024 |
| Decisions taken by Orion Corporation's Annual General Meeting on 20 March 2024 | 20 Mar 2024 |
| Orion Corporation: Organising meeting of the Board of Directors | 20 Mar 2024 |
| Orion Corporation: Managers' transactions - Juhani Kankaanpää | 4 Mar 2024 |
| Orion Corporation: Managers' transactions - Virve Laitinen | 4 Mar 2024 |
| Orion Corporation: Managers' transactions - Niclas Lindstedt | 4 Mar 2024 |